{"directed": true, "multigraph": true, "graph": {"pybel_version": "0.13.1-dev", "document_metadata": {"name": "GABA subgraph", "version": "5.1.2", "copyright": "Copyright Â© 2019 Fraunhofer SCAI, All rights reserved.", "licenses": "CC BY 4.0", "contact": "daniel.domingo.fernandez@scai.fraunhofer.de"}, "namespace_url": {"CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns", "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns", "GFAM": "https://raw.githubusercontent.com/pharmacome/terminology/3f89d31906739fce9678d868b6a599a851aa7c00/external/hgnc.genefamily-names.belns", "GO": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go.belns", "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/570376e4c233483b667eab12a1f964950368282a/export/hbp-names.belns", "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/hgnc-symbols.belns", "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh.belns", "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns", "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns", "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns", "GOBP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20170725.belns", "GOCC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20170725.belns", "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns", "MESHC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20170725.belns", "MESHCS": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-cell-structures/mesh-cell-structures-20170511.belns", "MESHD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20170725.belns", "MESHPP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20170725.belns", "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns", "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns", "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns", "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns", "INTERPRO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns", "ADO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns", "BRCO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns", "NIFT": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/imaging-ontology/imaging-ontology-1.0.6.belns", "PTS": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/neurodegeneration-pathways/neurodegeneration-pathways-1.0.0.belns"}, "namespace_pattern": {"DBSNP": "^rs\\d+$", "TAXONOMY": "^\\d+$"}, "namespaces_uncached": [], "annotation_url": {"Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno", "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno", "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno", "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno", "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno", "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno", "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno", "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno", "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno", "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno", "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"}, "annotation_pattern": {"Species": "\\d+"}, "annotation_list": {"Duration_of_Chemical_Exposure": ["Chronic", "Subchronic"], "NIFT": ["Positron Emission Tomography", "Volumetric MRI"], "Published": ["CDR story", "Epilepsy comorbidity paper"], "Race": ["Caucasian", "Chinese", "Colombian", "Italian", "Swedish", "Taiwanese"], "Condition": ["Normal Healthy State"], "Encode_Feature_Types": ["Promoter"], "Experimental_Group": ["Physical exercised group", "Sedentary group"], "KnockoutMice": ["App transgenic"], "DiseaseState": ["Early-onset AD", "Familial Alzheimers Disease", "Late-onset AD", "Mild AD", "Moderate AD", "Sporadic Alzheimers Disease"], "FDASTATUS": ["Phase 2", "Phase 3"], "UserdefinedCellLine": ["293APPwt", "App transgenic", "CHOAPPsw", "INS-1 cells", "N2a695 cell", "NT2N cells", "Neuroblastoma cell", "primary cortical neuron", "primary neuron"], "Patient": ["AD T2DM +ve", "AD T2DM -ve", "APOE e4 +ve", "APOE e4 -ve"], "Developmental_Phase__of_patient": ["Developmental stage", "Old"], "Transcriptionally_active_region": ["3 prime UTR", "5 prime UTR"]}}, "nodes": [{"function": "Abundance", "namespace": "CHEBI", "name": "1-(3-chlorophenyl)piperazine", "id": "dd3643d47dcd71d544e6862f92d1e380ab109986d8f590c5f3bff8d4a79e3a82cccad93b1fbdc537b0d2027663a6b42b9780c8ec222cc1ff99cb4cc92822dc20"}, {"function": "Abundance", "namespace": "CHEBI", "name": "EC 3.1.1.7 (acetylcholinesterase) inhibitor", "id": "f5115583612f3f2c40ebc54f2c528dbe7732517483538bd78de15d36df42904885a4fb82e5b4feac53e21bbdcf5c7e8e78c1985c4ff40c3fe99509119cf8984b"}, {"function": "Abundance", "namespace": "CHEBI", "name": "EC 3.1.4.* (phosphoric diester hydrolase) inhibitor", "id": "42506aa0da95eb80d2c4fe71f00f4823420882a78e4156a70cb42d1f9eac47834ab97686475f3e25bd8b979d9e40aa1bae0489b6685f5363835c9ace80889da4"}, {"function": "Abundance", "namespace": "CHEBI", "name": "GABA modulator", "id": "38c1f89d859a6b5a476bb509eddf621025d3f5a5a92f1f659ea83f6135c69da1ff46829b91f2133788100ebac1b56baa90c7b8f6180d8bbf2ff65dd9a1656098"}, {"function": "Abundance", "namespace": "CHEBI", "name": "copper(II) sulfate pentahydrate", "id": "29db84f0b573f34f0fbbbe5d3557c5a1a8c1750d192d8cfa7114fd3c52744f9c30cd2bc3aac3dd4962ddb4aa11d799a53af5de984a9b2f7cddb8d43a02459c73"}, {"function": "Abundance", "namespace": "CHEBI", "name": "gamma-aminobutyric acid", "id": "9583f9418a889245078b43a5744b3aee37f76bff3bff369f21f4091c2ad475d69415b09ff3b3b7e7aa6014f4e5dab6706477099218ce8a665f6751daba94e6b3"}, {"function": "Abundance", "namespace": "CHEBI", "name": "glutamate(1-)", "id": "fc1b84427efecfb8e3a837d65b6e115ffa8c7fc53ebacb54b967fd3aaafd25a6f47c147e986961e53c4ef1d5c36420fd9194019b5f81eeb5d33310f314818875"}, {"function": "Abundance", "namespace": "CHEBI", "name": "Midazolam", "id": "50d37c4e04e33112fc6349a41a169485bece52df54deac507dac758bc27a224c65f830033e91f96cd4f1903b5e246c17e2206f2947e20c7193c3bcfde191693b"}, {"function": "Abundance", "namespace": "CHEBI", "name": "choline", "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"}, {"function": "Abundance", "namespace": "CHEBI", "name": "estradiol", "id": "904ad56311bf85f6b904e16f8c23ba43255d705b6e623b83cc7002fea20feeab61d0ca62933f1ff52578a7885c1af9372264dcbd602303ede2b77e6e6f260a7f"}, {"function": "Abundance", "namespace": "CHEBI", "name": "etazolate", "id": "956dfd0f18fff924b897a8a4e11eef3677e8ec58845da4e7eb8a89bc1bb58f7c79f2fb810b3b82eb5b889f18359590a98055dc87ecb33ff226e89d2439f5071f"}, {"function": "Abundance", "namespace": "CHEBI", "name": "galanthamine", "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57"}, {"function": "Abundance", "namespace": "CHEBI", "name": "nefiracetam", "id": "7f3196ad00a4b8a75e29e44a626e93fcda0f2cb134af8c104089342b21c96731807b3ff9e3513070762c21b58fd4cc2b16b6df1c9fbc061a8176113f81e4b3d4"}, {"function": "Abundance", "namespace": "HBP", "name": "sAPP-alpha", "id": "7e0d346932e47222255dbd0e3b132a0dbeb5ba12373ac498350cabcb9d55c68f9de35471d8a7b9d9ac04e97b62b9699eef7226e0a7827d4b6be0d24acb31e70e"}, {"function": "Abundance", "namespace": "MESHC", "name": "Glatiramer Acetate", "id": "9e34ab7d9c0c52a2b76817924d903a2c3d4e5ca96fc1c5cbc0450a4fdd4f64828fe75d9e7d7cd0f3afeaa9560004d9e90b7f27a9a6f0426d390487820d48c91f"}, {"function": "Abundance", "namespace": "MESHC", "name": "Etazolate", "id": "8f5d170dcef171c9e985956f872ab40306fb005b25e7e34f283530c2463d9546a28eaa2e7bae74cf8f569e23ce95c7150a8954a13982a3e45f1970308ab94584"}, {"function": "Abundance", "namespace": "MESHC", "name": "Glutamates", "id": "516e9f73525ebc6d48e0cccded0a7207e84d289c1970ad1aad73284ad12a5d2ae0e5c3d118e89d9ee035e279db5d142a428f5afad709540718ab5443fb4254e2"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cAMP catabolic process", "id": "02ce2fbc35db8f2c219d1cd02465fcfc05161812ae0f411b712ff1f10e9bc5b0aed6c0d4b1adf5afefb205810b9cd6e28eee69b20d588f5c3a9dca625c6085a6"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cell death", "id": "e9c34894f8168b5203457e34ed316d9efdb8fd1ea105df0abd94b75fd8903b1e251ea98a878c68eea11861a5298f3a2cd1f1d1a9fa96e59cb4e504b9d5c71780"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "learning or memory", "id": "b9dbee447adb27aa88d06f2cadbafc23cae4f0dbdb429ad18224de98446db263210d57acbab4c70950c67df221fa44cd2b1fe11d0994822840be54b6ae20a973"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "long-term synaptic potentiation", "id": "c517c6e0e463d901f48877aa1554268a175cd003b0d8608ddbf1a6942af89257b345ee626cf4d07825d768000373cafdab884ab058bb5ced4215455e19b6e7e2"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "protein kinase A signaling", "id": "64eb3374b99ad1c1012af5452153a43dbbfb2254db5a022ae9525190d5ed4c5fd3a341b4c8469a2827729f754f620b470dd47d90a68d2b07b71d4598185af6de"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of neuronal synaptic plasticity", "id": "55b2270770c79d64e77a1658ec70dbd6f20f29e2b55e6a57925a8c8b9acb8b56231d1936ee29006e5cc6c05c36b3ed1e0c5c15df3de5cab0e94b150208fb61a2"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of synaptic plasticity", "id": "20ae2e31a66e627912482dcd89c85cd4a7abdc174d25d479bf5935b69f385906a6e21e7ef6ca1503f584a3d31849b4ab2b00a5ac2ae696c877b6924acbdde86f"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "synaptic transmission, cholinergic", "id": "1964e3b9b922a52efb1fb0fa6717cfc5689769dbd8e1569416cb67d0cbd294e1694519e5c08cae2b6895e007f265c1a47ff16cd84a196d2e458dab450d632a33"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cognition", "id": "7085c04c66ff00d9ede4223662139766ae23124164f0ef453fdb23a5605c09df1809749b89f32471228956018a87d82e70ba03f41ce127eb1e49a4d7b1519884"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "learning", "id": "ee36290ab8226f450927c8f0073441e739a71eb8b905ce1e756df6ee75a571e76233bf7eeb01a829aa10342883ae0eef8728a3920800c85035fa43b364c2de13"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "memory", "id": "2c0be3c3d7742f81a705f9ed3b9ae8ad529994d220b57b3c46cb1641073373cb3579b3c8ac29e9512cf6f3e2fd2207d508591b3c588d51484d8f1a21d05f1c8b"}, {"function": "BiologicalProcess", "namespace": "MESH", "name": "D000066829", "id": "6ef71a95d47c5d6ce72365c206a8074d5788ffbc8eb64411f72bcedd23da07434900c470e1a48e4942c7703008d213c0ba431a923a8f6f125441640db90a98b3"}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Neuroprotection", "id": "35d92ed7ab0208cdd5e3a92535270d201164e5f99005da9649b82ace2286cc6705326ec6a88a0d5f746b7565c658aad52423c2281f2121e184d2a9bacaee43ff"}, {"function": "Complex", "namespace": "GOCC", "name": "GABA receptor complex", "id": "4caa89b37e79df99888d7a18406e46e4e21b769d41041cdba961a87913c3b2f1c34b6927fda653cf45105a688c73702291f9edd0a2e1fc53adcd24a58339183e"}, {"function": "Complex", "namespace": "GOCC", "name": "potassium channel complex", "id": "6d56457b0a9bc3c47a85099ad1cbdffcdc3c1e1b9c3fd98a999fde3bcb9cd330bbcad5ea534712602b550f1b958d552fdf061713b9496a2b4253469d9dd4f008"}, {"function": "Complex", "namespace": "GOCC", "name": "proteasome complex", "id": "948bc2617d7eb386907ac4f5b0876a01ce3d5b6fbf2520ef959c0b6189870c20554e30429503ed2ce5f42a9e4808ca2d7f5062caeae5b80ced2d4318b31351d6"}, {"function": "Complex", "namespace": "SCOMP", "name": "CAMK2 Complex", "id": "f6cd184703ac7d520e77b35cace10c6c1c9c9cf6a4a147c0295b7314e57ca0978bbebc2cff93645ab3c8c3d953fcfb5bc196ee901840b8de169c44bf64b211c3"}, {"function": "Complex", "members": [{"function": "Abundance", "namespace": "CHEBI", "name": "nefiracetam", "id": "7f3196ad00a4b8a75e29e44a626e93fcda0f2cb134af8c104089342b21c96731807b3ff9e3513070762c21b58fd4cc2b16b6df1c9fbc061a8176113f81e4b3d4"}, {"function": "Protein", "namespace": "HGNC", "name": "PRKCA", "id": "5219ddfd45ab407e59a16ba37c54192d6d74de0a9d1658b16570713f21507ae5bde72c5b85c3a4d93e811fab5db2b129ab97648a370a0fd2add9239eff17ad06"}], "id": "c81cf3fd8fb80df2c7afa0442f88418db31556fc395e8e784bf032df0d1e1821e388d37bc6b5c5f98ecf2d1f24ff0d693c14456faed4beac28e183fa3462296c"}, {"function": "Protein", "namespace": "GFAM", "name": "Glutamate ionotropic receptor NMDA type subunits", "id": "29ba27bf8a73e82ca127ff15cacef709ca5ace693b4fa6e454716ed3e12ca06aef2dda0a21d01b187cf5f212cc5d8737edf1286ebd749aff0600ab10febfc806"}, {"function": "Protein", "namespace": "HGNC", "name": "ADAM10", "id": "bd47ad5cb480f1f5352dc919edee75d506c0cbfe44ed1a4c53dd9e9c7f7ab383ca2111205a1c12d47100e58c5a5d80d33a56372524bad144da469c574748e8c1"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA10", "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA2", "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA3", "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA4", "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA5", "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA6", "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA7", "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA9", "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB2", "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB3", "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB4", "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"}, {"function": "Protein", "namespace": "HGNC", "name": "EGR1", "id": "9e06a6d40a8c0e52e3920705342d4ddef7be8aec5acbf83dfb9473e9fdfbc339a1beddba9ef7ffbc1a4fc255edc38098cb1d9acd7319bf7aa22c0b02bfe2ec94"}, {"function": "Protein", "namespace": "HGNC", "name": "GABBR1", "id": "b46c3f5968292ad2a4d73e5491b3403a477c704cc3cfd6aeae570446d7e0126333f754146ab96207a904a31eab80250fd9b8c0c2484e5a4281220f30b77df71d"}, {"function": "Protein", "namespace": "HGNC", "name": "GABBR2", "id": "17fc7f5d0670c4672164ba5eae2724437d03577ae22841d440ce6c181500569ad3c91780f1a223397662f2c80cf1220143a0ec6c86eafc421f730dc3f0d36478"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRA1", "id": "d7fe2718665a8169b55ed75e57ccbd07bd6bb0214271397dcb1f71f199da7646ffda8ae406e0b18b927a8b5cc05093d35854beb479f79b43b6febd1428d1ccee"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRA2", "id": "d4eba143aaed689cba7713c337c15b2c7a687b3572d1b0efb118ae0204e6c2e114643c83013dc49b0dab0d2389453b8955736c9bb2f537c35420ce8fa5761d5e"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRA3", "id": "974711b61da8bec40f0263690dd4bc00024239ab960462050ca088f4ae5e20c7092b978ff114e6cdd9e2dbe63e6bc941d70d253e989f188b16ae89607f189430"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRA4", "id": "7f44ddc2f9bd854ba369dacc8d45db24eb32ff82d35f626595bbd8bc8f01c8b06eef38a91fc2363584df1a156a9a6517c8542da828544a3bca8bed8cac6ae07d"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRA5", "id": "61c4c1b611d048dd029ac0978550584810924a63bb7f49532f19f4015686fe8db4b8cf510dccfb6b28cc360ee966b4cf82f85c9862252f3d55bdda6e3b4c1150"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRA6", "id": "0329ebbe7bd9e78e4c0a184cc6dc6c8959059865ae275a64d7568435c90269e16312ef0c88b9f46ace89b04c1e4ec6149266f3606de7eceab0965eec303b99e4"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRB1", "id": "304e7de56b59111737cf86cdd2f8c1d68bbdb52b38a1a700bb981a111a358a3933dcac0706708f61e893485cbbaeccc9b6a494d5f24443e369d8a057ef69bed7"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRB2", "id": "a5b3f75e14b98ef118b5f9d249443ae0ab3e4ed438693028a340cea7dddc749b5e966833fbbb8b22bfc375b4270bf6c0ce1818741c52c258f312d64b3c4ab156"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRB3", "id": "d28217c877ab52fb40ab17d3da3aee99d26ffc8d49891a223c25faede95f163e53272eea8d0dadbd5b2e2ef475c5f6a7cd549aa0b2376c339f34c800adf6c751"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRD", "id": "6c06da2ba7f7b647c1fdd9b98a6eed09e2cfaf500e884755342cb72da0458f2b77cedd24b704feb8a8a1bfa89de375525f0ea59f3fbc817eba7705b0f793692f"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRE", "id": "995f79fe992000bf21eedfb99d7fd929f1905543febb21efb9ec6137d67dde58840c231dd3a62514e69d8a60189f20e580cf36c107f66a9efd4812624239db65"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRG1", "id": "8ceb48ac9f1502ea1c57c934a33a3afe12a455ca136357bc1359a6648c99c247c9367e094b1fbbbea62a091aec5a32f81f9ae25169f174bb7a83b48e19b1a6ed"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRG2", "id": "87b492867d0cfa09a25cbc4d9fedfb1c8e5eb700cb6dd61e1e50d8db4965604d5e2edfe66994b64c1e57c118e269060532b7aef4d3a37d75b1d40cf8ab37c345"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRG3", "id": "3428065405fb1c6614ed39b698e25b0c8d10be33c57bc64e8aed4e79b90903546dd3e5e37fc00da4c5d263121a116713505aa515c738791791a6cb6378172053"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRP", "id": "826d67714d1bb7c2f75ef53f598fe2abca831c74b6b3c19d9fcdeeb6310990c1119350b000273ce14bb2b8dc9d764b680bf08118bab7bd4eba4d0dbf5186f422"}, {"function": "Protein", "namespace": "HGNC", "name": "GABRQ", "id": "57d3f299619cc880195dbf9f7f0319fa6c8a229d601f0142cb8a79e5bc415a4f243fdd2f815f9dd35b4ed2f4b8e0ada8793d451c138c1e219934dc8b6547e7e1"}, {"function": "Protein", "namespace": "HGNC", "name": "GRIA1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 831}], "id": "370b4b58f8ead79bab47752d2035d224e347fcce327d50bd31cdde5c6dc77c837c8a52474ff467cb9d180dd3f7b19a4ba4901e77d01663b2e52d9f1149b5fdf0"}, {"function": "Protein", "namespace": "HGNC", "name": "GRIN2B", "id": "dd9815c83f93be031a07df6d80146f91f55b3ad8850ccdd967007048fd2354c2bc2fec0dd0a8f428c9c411568fced227500db81dfea20193b9138af7008527a0"}, {"function": "Protein", "namespace": "HGNC", "name": "GRIN2B", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "270240c9eac99382370eab682d79c04d9a9a6c1543d1f290ee60f8d14d4260ca7cc813d5ca068dc53454a45649eb2fb277199042322dee91acebb58d5f1c4a4f"}, {"function": "Protein", "namespace": "HGNC", "name": "PRKCA", "id": "5219ddfd45ab407e59a16ba37c54192d6d74de0a9d1658b16570713f21507ae5bde72c5b85c3a4d93e811fab5db2b129ab97648a370a0fd2add9239eff17ad06"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN2", "id": "a48c939dd23656d3d74e6d0bec3176c8bcd8cdd2d816ac8f90fc78442759db35852078eebabc5fbc1e2f4255a07b6b397daae3f058157269dcc5c15cf7b1149a"}, {"function": "Protein", "namespace": "HGNC", "name": "TNF", "id": "a262f5edbfb734dd0ec9696a3b78644fccfb4054a9cf9225beb17c33ef416a75809ff59ec1646e29a3cccc804c9294f8d2c48120af9f5ee98e764a584626426d"}, {"function": "Protein", "namespace": "MESHC", "name": "NMDA receptor A1", "id": "9725ae65b18412d4d9ad2698b080da44a7aecac5a9a21471ff305d21e0ad8747a1fa5364669a37baad8be3156216400ad707a1a487cebb50afed2337093170c7"}, {"function": "Protein", "namespace": "MESHC", "name": "NR1 NMDA receptor", "id": "4be6db4e45c7f2a93a403d12071f06756794167dcacb9fdfff0026c0e07829ab022258b636c1d78985bcd803e28136ae53de5d6e3d5fee6cf01eac40f298cc8c"}, {"function": "Protein", "namespace": "MESHC", "name": "NR2A NMDA receptor", "id": "245567c4c7c11daf094e6d746bd3b261aba2e03002263a8cd513b4093c42fc86848f583673e835b001984ee84b3fbde4887b1ff9ff039c206ea0dbb35c332788"}, {"function": "Protein", "namespace": "MESHC", "name": "NR2B NMDA receptor", "id": "e176af5264644f3bafacf5ca3646d8f8e4d1ec68e9587a004af2939ceb2d6771d5464c1fbd668f1086d4d670f100bbf2dda7d0d43b04900d5ccc08c1861120b8"}, {"function": "Protein", "namespace": "MESHC", "name": "NR2C NMDA receptor", "id": "e5a6585594c75c7d1b81d593e8104ccf94e7cbb2d7d08cb0b8bb08040b531e30e6dfc632af46007a01df06fc80cd4ac15e4f7cfbbc552ad70b9eeb769c40b78e"}, {"function": "Protein", "namespace": "MESHC", "name": "NR2D NMDA receptor", "id": "343fe851a1309130d7c05b0ab033d6b93febf8dc957a507e4c20a1d078a53b10cbaf2dbb1c19bd0784f90f6216f5028312b57db6011ada9332f56f1a12274ff8"}, {"function": "Protein", "namespace": "MESHC", "name": "NR3A NMDA receptor", "id": "c189fd640f309cd35896c6c9126390bcf85a6d04b9c88676dff9e9dbb62173ed148aa20047b5386ae4c392b0f17011be85a6e3ea4f84c055041e2b0afd8a7ce7"}, {"function": "Protein", "namespace": "MESHC", "name": "NR3B NMDA receptor", "id": "29a3f54c9e284c307af2e411a0e33050ccd64c719c33d1cd19138d3de78ecf42e581467c14287e060d205a488a56cabecb766b4e31edcf98cdb080a108781561"}, {"function": "Protein", "namespace": "MESHC", "name": "metabotropic quisqualate receptor", "id": "b3290d562565ba6f545506043b439ee8951293d5206a6616eb6002425e7635b7db8e91c61506f741ff97c17372bb52d6f21e6e674a55726f97239c1398360a91"}, {"function": "Protein", "namespace": "MGI", "name": "Egr1", "id": "bbe2efcfcaec37c2f54fd19fcc2068de70a97caaa65afd28ba330088b537383721fa1b855bcc16045ed83f79bdb99c10ecac82b90e01c8ea1d30e33879d2f639"}, {"function": "Protein", "namespace": "MGI", "name": "Gabrb3", "id": "6fcb17148514419e089b37a9b9c6a94c18ea8532ec13ea833e67617c07c30601e903979e72011e5af07d5fe1eedc75d90453f5c6c469cbe69b5bcefe6c613c46"}, {"function": "Pathology", "namespace": "MESHD", "name": "Alzheimer Disease", "id": "0893d59040331bc1b155187396067458820ab2635e0138b840323082d33d44b964ab1240f5aeb64c5360e1340de40545835bc744c181abb910d64c923d55ff2b"}, {"function": "RNA", "namespace": "HGNC", "name": "GABRA3", "id": "219953892cd78d46da6eccc2dff620e3142f208f02172a38825b5331071fa3bcccfc45a041547de5240d6fac31007594f4af80cf03f7084a89a7aa3d8efc8848"}, {"function": "RNA", "namespace": "HGNC", "name": "GABRA4", "id": "51ab697cd11ce6ec516f25077995e31257ee6201fa3addd7c7408be3b35b95850f7107b8fe4d0e692f831a3ecf12db2479e078bfb8eeb791a963142ac18c646e"}, {"function": "RNA", "namespace": "HGNC", "name": "GABRA5", "id": "d3c747c36e5e8c30517125237293693b173570ea1ea966e866b903bd9962f22097f4d034a6fd2bc170161a0219d68780a27480ac737b6010a33b63c966d67d53"}, {"function": "RNA", "namespace": "HGNC", "name": "GABRB3", "id": "826bd720fa7d064b82cc07a094523beaec858c9bcee06e4d3333d3f9eb71789b24e29e1a7725da5dcd380f07ca723c16c66cc8fc1f9cecc2767c78966713a468"}, {"function": "RNA", "namespace": "MGI", "name": "Gabrb3", "id": "dde3af69f3155ea6ab609ef2e58be8fd9236d6104f460cc06e445c4ee30a65bb53f1115b1595733a7745601f9024aee1c30a49047bca701bc52f24c45c9e9b9b"}], "links": [{"line": 18078, "relation": "increases", "evidence": "In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true}, "Confidence": {"High": true}}, "source": 37, "target": 70, "key": "a9bc5e54f33521a72243a5daaa88e281c8739abef77d0cc6377b33c0283481a9473046f39402aeac7b43d5e1d4424096c64ef766472ae1e26b03a3bb901cc1f3"}, {"line": 22216, "relation": "association", "evidence": "Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"Epilepsy comorbidity paper": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 85, "target": 72, "key": "13c1b1c5bab2e5b3c79724d32001ce542fcb06fa4ecef1a84e48e94788e5097cf4f5fcf07a22de65a1a89231964970e63db58196ff78fd38287748ebd5caa5a6"}, {"line": 18236, "relation": "decreases", "evidence": "The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 85, "target": 24, "key": "cd35ccc953d0f8a85775261a53543ad320ae36c6d5e33fa39b0fc0cd688524e7f498299ba3390310c02ab817bfb1dc6f3c3dee1d92110304df27e1e61e7f4838"}, {"line": 22151, "relation": "association", "evidence": "In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.", "citation": {"type": "PubMed", "reference": "21969301"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Hippocampus": true}, "Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 85, "target": 49, "key": "81bcbc58ec9137f76a62c8d837c3ea221a6b18160153942310d0aabba9f3aad802f8f81da48eb6a2c41fa49f4ebbaabfa075a57ebb76e605890255ccb1c64724"}, {"line": 22212, "relation": "association", "evidence": "Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"Epilepsy comorbidity paper": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 85, "target": 49, "key": "c7c7cfb14272406ca193060aaab60ac2fcff9f3b8b2656e3e312988b4e9ebc1292899eb2de174ebcd237f442a0ff049ef9a369bb0031c8d18749bdcfd0406ae0"}, {"line": 22216, "relation": "association", "evidence": "Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"Epilepsy comorbidity paper": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 72, "target": 85, "key": "c5c6a6baee790272b8757c839480813bb588248480ea747c61891fc5393406971976374349c3543de3bce738f1f920d6507cab2422cc0e2c3f66776bd4b83723"}, {"line": 22151, "relation": "association", "evidence": "In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.", "citation": {"type": "PubMed", "reference": "21969301"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Hippocampus": true}, "Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 49, "target": 85, "key": "b3847b91a4f18b3654545fa8c0b4b08a03fbd6c11e6635b9980fc20dc9d6fe564d68a93f16511333375ceeb483545c8ef75e36171579df02cb7e73cf975231bc"}, {"line": 22212, "relation": "association", "evidence": "Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"Epilepsy comorbidity paper": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 49, "target": 85, "key": "cf677bda4ea925cad4f6f0b195213f4831c31b99b87f423c010ba5389142c8833439a31b49a8591132631f82aec09bd500d1adb310adbc88e6c2060dba035e9b"}, {"line": 22018, "relation": "association", "evidence": "Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 49, "target": 22, "key": "0108b7c02e36f1fcbe2c59834f360d885c7ae09391c8b97c1f773af7a20d639efa5542d60c9a242b34a3e3cfa5fcbdcca64c4c566c91f08304027d2dda5d5bdc"}, {"line": 22026, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 52, "key": "43eb2f1ff8f5910ea866f15a47f1453120c6aee4d763fd63b496307b8fe2794a82a3a75d74b1f6ef1e59d19db553cbd72afbaa0fd295e1eeff820217cbff6e8a"}, {"line": 22030, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 53, "key": "376a79a1b5a3f097fec1d11a3f28f546b5bd30f912a845d9530801b8cbf98b316ad5b1059f199ce5c0273dc649e902850f935bb29b1e79d18e9f3bc52c909d65"}, {"line": 22034, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 54, "key": "48424eef938d519e294d538a4a7abf7cc2f71ba69485c025fe3d82259c1f550838cee937136c6dc3f77f757dc1e7b57dd027ce8c148a05cb93693147ac8ee1e7"}, {"line": 22038, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 55, "key": "26094542472b7c1a7245555f620fb71ff3d26c82f8079448cd868c647f022b3a721a4e5e7a4fa9d998e7f5c6b93a3e3115db783e61d9c981ffac03344e18a31a"}, {"line": 22042, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 56, "key": "5da9cb03456c79890a3d6e37d6ea8fadcd116f9fae12d87bcad2d35d7f279c30ac887679eb33154dccfa09b973a58d69e72d76fd2242bd382322bc0f9685546b"}, {"line": 22046, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 57, "key": "e96e80837dbe54b59689a466733173c05d4b4dbcd657333c7a6803c48e621b7fa12b4a9a744c5f101b221a600dbcf37fd3de91262a47c0f1fee80aba79c6111b"}, {"line": 22050, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 58, "key": "39db27be31be975ceaadd6a64150007747b7d19ab7bf56e00efbf35f66ce74bb4f9a90e39f314b98691be27c7a6882de254ebdf98e6923724099ca282e5779e3"}, {"line": 22054, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 59, "key": "d888238df6b4f833dcc54b55dce0f4abce98373a5c9aba4efc75f8140d715083c3bb5c77d34ab09efba71ccb6a7395167b60bd097a629abd367b71c35ca520dd"}, {"line": 22058, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 60, "key": "2d408639b650e42133d0ec076d214b89a78d9ad277793206be77af87c15043e262ce314511034718d0ce92f891ea3a1be5e215f314090c0204d054655c8566b8"}, {"line": 22062, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 63, "key": "b57d9121f5f72cf8d649b02bd7d9028b794767cfbb8e98135c42e87741a2617fc0ea87140fefb3c67ca35638eb8e924fb0ba59c353e8e5081f8d8ae2b7a5c8de"}, {"line": 22066, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 64, "key": "407ce4af7f1fa1f182ebcc97ddccbcece0b0b44213912850c1fb937cc8141f9b3e9b6c97354169b56f2bbd351f98e8d86913053000216b5139dad8d1791e4663"}, {"line": 22070, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 65, "key": "7a6d0b24a6a0437b98f202ea9e69bd21e09e253c0f806b6986309cb66df74c1ee430342719d7cf249276b41108ae456c4a76844a2c0c7615068c785091b1c047"}, {"line": 22074, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 61, "key": "f876df739687a0b74dbc6499a2a02200f1f46b1ac1f65f6ed67ff49d0e3a99dd107249c9c725767f593dc47545688ac033d49c32bf0e6620e30eed1992349d7c"}, {"line": 22077, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 62, "key": "04384d8975728016cec7ae28159a213111e7c90c2e4586a1e8558fafc751bdf9c8b99fb500c5be6ed7769b7a2b0bb5cc40415a518afea44daf8be0e20d3863b2"}, {"line": 22081, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 66, "key": "cc4eb32696314fd32bc122636d155118d222a10ea6960a703e74b871b9bccf7a877c176f76d5cdefa6ed88d4ba9b2eddd00b761a1568eef7569deb8f1245d520"}, {"line": 22085, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 67, "key": "871c3458f8e591baeddd680cb65e80a889784b8e2a472e138f3b02a9e9b44bbeb3d17a128398d3e6a45b4db337d2996bbd0507ac8efea7288d1a47167f2a4af7"}, {"line": 22089, "relation": "regulates", "evidence": "Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 35, "key": "5de42a520b19d676c8054af92a33f9f9c81acc952d7213e5bfcbe95955e5a82034e8c565713ac525153a353b175be0dab0e7f3bc04e4ec70cdfc1647c82eaf4d"}, {"line": 22099, "relation": "regulates", "evidence": "Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Ubiquitin degradation subgraph": true}, "MeSHAnatomy": {"Neurons": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 32, "key": "ececb4804c93a5a525ea4150df14a559919eb014ad4b595c5a901c48ecd0d25b529d70ae071f640b789784db3d9ad00fee8c15e0a408177b3cd0e00d337cf7f9"}, {"line": 22187, "relation": "increases", "evidence": "Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.", "citation": {"type": "PubMed", "reference": "21969301"}, "annotations": {"MeSHDisease": {"Glaucoma": true, "Alzheimer Disease": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 49, "target": 14, "key": "c35455b4511c327279f00705fb4489097cabca8c8ebe8d1f932ec07780afa4ecc2072a0f9ffda1dc45329f5da7ec6520062411956c06d7c8cfdcddbe6f07b1fa"}, {"line": 22208, "relation": "increases", "evidence": "Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"Epilepsy comorbidity paper": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 49, "target": 72, "key": "a0339c7b0e4ea5fbc9458452a67e4ab2005b8fc21380cb0fae13560fa2d31897f3461e9a4b6ae9891efe3d428cda9fcc876e85cf71869268237cd192a77cc8d7"}, {"line": 27583, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 18, "key": "06f9fff4da2435c125af6b96d43160c4a403da0d5beccae7f54d11901be9c8bf092ae9fa33b87751f61b7abc4f550a98a0d098b87addce2363c881cfe3b5d00f"}, {"line": 27591, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 74, "key": "dc772cf2804cd2360a5e164d9ff2bb5ade9a566d59566ba0f1adc13c83bd9fc3f6a2b9207963977482b6ffae5fce856364562f6d911a7b2e848165118ff3167e"}, {"line": 27595, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 75, "key": "56060183ac7c541777c75f36b2768a46fa3514c3c59fef96933a11537a61d52a4d6753fc9d30e22cd1ae1abb570db61a95085a35e3bea2ece882a10c2d9ed9ba"}, {"line": 27603, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 76, "key": "75d26f312bc06c1f272575902f05ac51905ab548ccb44d340bb48ef37c0af66c308ebf83a70ecc862b233794bfccd6a8c54f8210b8886521707620c10629bd42"}, {"line": 27607, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 77, "key": "9dba321a8b8c45ef8e7d82a4d2e94f91b6741a028e832c5c44e60c0181cc782a4722f928a21bbf0ca1fb70f7bed59a5a8d6454f8958367f99def08f2614607e3"}, {"line": 27611, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 78, "key": "58cad1aebd1ff3a380b33e192179733ef970c242903647841543d3ac0abaaa4bfa99064b158c03241e38e9dd9e1c5564ccc0809664ab5dc997c3a03e9dd1eb50"}, {"line": 27615, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 79, "key": "75e5fb9a8a8a42d1c28de50c16226ac5e253f9695941523e95c40266bbc67f5d675665694a48a6ff61c1f7ec212adbd0e91c8431e44744955cc94776d08e548d"}, {"line": 27619, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 80, "key": "cf34ccc26224c0fa4d4c31428633dd31634be110f50191f2f3488ffd511bb0ebf29eb8cee0c6b482d79c9511d2136d590a09cdf4ed754887361d153367ec2f82"}, {"line": 27623, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 81, "key": "41d61ae48bc68f40afd49f264dd040892ac8511529f5061609eef312b8a088ff4f192e3665f82a9c6f65748cd376e3724ce63b638b0bdd716f132abdaef28752"}, {"line": 27627, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 30, "key": "7e5f94537a006f69576ec3b4d25a7d1fee3403f511437da9f45c62216b057b047ee060dbcc94ca1c729c5c715ee17b55697df73628c2a6c80ee7e921bde992bb"}, {"line": 27631, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 73, "target": 82, "key": "2d959bc80a2548802c61c1da060dee82c886d83550c526b4848af570221a0cec979f8a9cbd023615614908345a4e6887588dd6c90151cf0901b1929fa81cbf27"}, {"line": 27660, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 52, "key": "c488504030045fb2e592c863b4c233a92b12e288afe87936533f2324779a2da6b922b839a7417a8fe21115c14b3876997b370a88fb02a37c00e958dfeba54708"}, {"line": 27664, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 53, "key": "2000c42cd436003ccab556fdc42d0ce1b5d98467bff5fea778606ef32a6c7c9e2555bcb793361e32a051d6498cc9f3b97c07165e47babd7b2a55f76a2bef6bc4"}, {"line": 27668, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 54, "key": "4298f5a7772d532e0f351d3e0e056d616053c28e44056a400e08b72f26beccb26dd22811e52910c78c33e213a494f0ad10df6e1cf40b8075535720cd59f93a9b"}, {"line": 27672, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 55, "key": "8cfce9eb83c31aa44faeb6c74a617954d522bafdcd89d77aa820d0aac6f60bfc0418793d6ba145c9b851b0728b8517bd43f21109bde18b01ccb544796f31b41e"}, {"line": 27676, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 56, "key": "65eee6c047497545b7c43a186eb6c45cce4a057599edd8580c31798891e810d9bc5b774bc0a35b1b1496fcbfe1224827416310003d31571eded2d97ff7dceada"}, {"line": 27680, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 57, "key": "3332dd1a3f0018de409e43c5c048ca091010866f56cde60503d553a5040addfdb1c85d581790585ec8c465c03d37df69b0a37f412ac0fc43361fa963ab1446aa"}, {"line": 27684, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 58, "key": "c4a901db85d3dec56514c96a83630fb785eab69ee381b044c74b2dadea6e256c97f9a0c97480b84d46b8ee2adfb1ca35c511850df6e788e3c37335ce454ed66a"}, {"line": 27688, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 59, "key": "7cd8a8ddf0146f69d68d30ed595921b1d2d3d7994a08f69208fe39e9097eeebfb0de1ee5ac56dcd1419b98fd9d03b5120fbc481b9f474c7a92b81de73461b468"}, {"line": 27692, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 60, "key": "c401721cbd8b968b72e94fccd87ab105619aa99208d0085dc2b2f3e466cc1b364e740ba5cc442c6e229d2f22340732d74016e427739db8ae76263a685254719e"}, {"line": 27696, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 63, "key": "789359b2662c24a80ff12bebc323963d4460eabf67287cf3276a39f36d9ca0a8ac48b72bfe0adf0bdf8f0d4ac0dff0b4b639dccea2db5cceadd6ff388cb4fb9c"}, {"line": 27700, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 64, "key": "d1e6dcf76221c60d0bdcef8fc61a148ecb031cc9153bcc6acbfe969539563659ec3fd4bc94cbc217e0b34a50b956b1d9aa8cba5708b4479fbe3e7bb581c8ffcf"}, {"line": 27704, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 65, "key": "200424d05e6a56f9403f55b826e30fe748df455e5a3397b1b5bde071e8bd2a3ef565ef0a5759f2157285651b0222d34cdd3d85ef5d140018aadadb49871b78e5"}, {"line": 27708, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 61, "key": "e3fd7e19013d9b06e6ef15d377839f9caec820c89bde6a5de280853912fda937d7f03d9863712b28d53137556fe25a99ce8cef9b81836e86d0321ac1bf711358"}, {"line": 27712, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 62, "key": "4fc3ba5f66ef5e1b1071a51ecfc5bcee2e42a758b44306cc3db3f3ef9e3d3f526a293f22c98f2f2836a23bfd42a7099276418546e2e2ae18b42c9b1332cc5f4f"}, {"line": 27716, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 66, "key": "7a00f63dd18b124480ad6e12fffa2d285d0fe7f855cb94e12848db9a4a0fc55591ce6c6b1fb8922b63a705a1a13c515e55f8e9b236dbab6808a55e2dd7ad4f66"}, {"line": 27720, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 67, "key": "90457879cad53048052fb8ec80319ff0f5b466179db3e200449651636ddfe74f28d78dfaad8ee3d1a355b74831b9a54129e31d5080e8ac7241bbe8867afe255e"}, {"line": 27724, "relation": "decreases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Tumor necrosis factor subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 50, "key": "427b474ab30b4d144d4d1be4f090ac71aea96efd1313647254ffe06e3704f3734c9afd04118a0091f948d64479fb2f833da927cfea604ed4153bfc089db94ead"}, {"line": 21948, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 52, "target": 23, "key": "3dd01e360537eae7c434038e7c32f7c19c66128e3759f6468b1c223daeabb07242cba94bea2f14cb2e60415fcb1c0e02a1db6d37bdfaa0ba866716d56831c833"}, {"line": 21952, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 53, "target": 23, "key": "4a6b1eb33259fd98ad028fe084790c6e3143c5610347807032dc24ae810496f6f931c08d61a45f23c75431f7717d5c17bb2bc597d80db973e21b33656340aef3"}, {"line": 21956, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 54, "target": 23, "key": "4b2f76ee600ce06b55644b967202820a1c5fd2db8277e76f0c1ef1c3e7acdfbca033a817acd2893bd8274b4f271c6e0f145fe4509288c1e3168f9b10b3f38b1b"}, {"line": 21960, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 55, "target": 23, "key": "962126a61cb6149f994e7e28d40028b4e4e0de5e88aba7c60bfd3e7813f602306dbc8ae917ce378a76dfcd03cee37f227aa927099b6eb6731b4e527b707ab17f"}, {"line": 21964, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 56, "target": 23, "key": "63cbc0748e7cf48413018ecd73d9dff62965356a29a08bbf9ee7d48eeda7e9c5f3e3bbc4fd549f85fde1852f31a4b609f9ccf7839d0c293895f44c4b7d389f41"}, {"line": 21968, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 57, "target": 23, "key": "b3230c2bd02409e62809cab45f628ddb99f2d9455f1c9561f3ea80387751ecd45c29a20ecd1a0a70bd94227943eedcc4dcedd4b212e48769b2c7122cf3b2852b"}, {"line": 21972, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 58, "target": 23, "key": "0c174beeac589682e45e5bf94893028be675d066d03ed11e28346395dbed9eb47af9155b07d3f4d156372e6fc791709e257b82a07057d8e418c97263eebdea5f"}, {"line": 21976, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 59, "target": 23, "key": "ec9dbeec9ee131577049612c72879f380c3037a5167a6a7c3a5fb27f9caa1b251b1a1ae77822de53aa2f4962aae02a23b1dfc84de53e1128d98937401b94a774"}, {"line": 21980, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 60, "target": 23, "key": "1017557f7e188e0ef36daac49fd3a999f808644c985acf8bee95c49b4629e85a643fdba4bb2055c02b2d3a9a8c4b00d4f83ae445efd94449989b03fca0b85260"}, {"line": 21984, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 63, "target": 23, "key": "d0583e8ce6809a0a22044ebef260262ff7dff62fb00927a4f8f140a6dfc7cab695ff2f0689eef98f857f319e19f2eb618ef2e6bf7f859eece2f28efdba720c4e"}, {"line": 21988, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 64, "target": 23, "key": "97782e37e3f0d004f3ef94b93ddd169addb533addc79d20f876e063505ae2ffbf272a0bae3d65162f20085217bb848f90afbed4dd10256c52716d1f43644c0c6"}, {"line": 21992, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 65, "target": 23, "key": "50b3acbabd1f7672313a132aa2b6108c6a2a302e747ad38a6e2d7b066f9b2943f48e4f6e8d2fcef5090eb87918faa809bb8c922f9009ce5a77bf6051f7ad51e6"}, {"line": 21996, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 61, "target": 23, "key": "df1ddfbb45b4480d7d129f517bee8416f9233ac72a648020ef8bcc62a0ac9992c60f3df7527f0c689b6ff57bf11577d1d36bc1757aecdc556c6a390076acb509"}, {"line": 22000, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 62, "target": 23, "key": "8b6e7b40cad9f4d2bf3bea3c27be19b7641f3897498369748051d0a922432f52c7f69f7fdb2dab634db392286a2cfce4f974a4ff3cd37fe6744d86d801da1c1a"}, {"line": 22004, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 66, "target": 23, "key": "974cf64a87bf9f6fe1df0c26afad579c06516afbffe6547a5231f915fe3440526e391da4be4975203143cc12cfbc3164b4d4dd677b7534aa2c0460977942ba6b"}, {"line": 22008, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 67, "target": 23, "key": "e594e7e6506ac4431b211b98959552828b692a304afd574c4dd7a9a9f94de78c718045b70bfb54c4b3efbda4b11a4f2261d6306a723ba897b84fb6392034a682"}, {"line": 22012, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 35, "target": 23, "key": "e5a10a596766543240b5c994a336efe40ed5653454c8ea52cae1cf818633c64a76cae68182f6848cb941fb3e84dfca8eee73b7f46af47df7198266ad00eee268"}, {"line": 21948, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 52, "key": "9ca2723b27e212d7ed66648cf47475c560f34df8a7dd0ce6ef47d47de82498ee297ff40d5a07b924253d5d197f68b30ceea4e34e80ec95c7535e087fef227a0f"}, {"line": 21952, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 53, "key": "50e8d4263d9aa546625a1d0dc9b799598d7931442a3796ea4dde82a36666755069a223772a24bb60c647a746efb9021268bf16a451b7e7242f28aa2037e23125"}, {"line": 21956, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 54, "key": "3299f9f926372ba776adac14f8208d9fab267f939f8421ce0775a869aa6587f38798078dcded61e0c974a2fd367dce86a89f90c810001c859fe6d987005e4d62"}, {"line": 21960, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 55, "key": "921a505d02e858d6b052e9a78ee6b9effc4f17edefb1f2086d091d4e4d9f80f6ca7e408222b03bce5495acf48dccbd85944140aaeeefb8faf4c67426e5987f94"}, {"line": 21964, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 56, "key": "129b13c01d8a4b5e522f4f425838cd245082b723ad0ca7b4bdd003b2132561b27d76279037a2c5f87a3c2a8c41bf2576ea79076bb9c0179c4b650a3c90fa6bae"}, {"line": 21968, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 57, "key": "a3d0ceb28ccbefb429cfcea35d4cbafd7fb5a5981608ee26a4b6963d876001449f171b12f2193d5c4df94a5508e26f76e3cf970333ce1e25ad0e6cb60480ae5d"}, {"line": 21972, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 58, "key": "4afb203a0f14ffba64af712c8bfea83fcf06095fea72a5536bc7e96290008d2ab93a7557da1a87ea2af19314a79877a7fa8446c02a46aa01fb32f5864459a13d"}, {"line": 21976, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 59, "key": "6fda61dc44d4adde7a11e2d90efba458ded5d6a9ca32fe83dc884bfcc61d2699ddc2a492647472b62c98b969d654e89a3e5e21879839cfdd5a2a4a26a59f3ee3"}, {"line": 21980, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 60, "key": "809c24a27c87e2e299ec9c31b13008661592cc0b618293b7d6fcc9cf35febe0c26472bbce2701f9fcf25a5ef9b5db1fb8e3ea321cce87445cf75592a352e30a8"}, {"line": 21984, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 63, "key": "9bd07cfc5620f71d9c02c8e1f95f2c6e3974d2e62ef14c5bada7fcb2341d1138f5b4185eb6d181aebf31c00637a22bfa04df4657b9d195bb80ad852be3959b7e"}, {"line": 21988, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 64, "key": "b4c1da8e233f658c5a9ca889a62a61207487389c57670d7ba0d5764eb15def8bb33ff2e56b793e8f589a5c178595f2de2f4a28ec16f97278f84053a62d1fc82b"}, {"line": 21992, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 65, "key": "b3a471a35df17a168556b902bcec978ef39d6d34ffd3cd442407f26c09ca142cfb2e7f33b2d407203eb8b11db276c637970bd388b506dd647741ff45afdadf62"}, {"line": 21996, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 61, "key": "120d16c6bf43cbc47fe55d7df28aa3768a5c05218d8084e372bd4278b73c80a2b73ff4c395d5cdf76875ed8e10b99e95406153ad4fcb6e3fe1a7a9bd78e24aae"}, {"line": 22000, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 62, "key": "4baded82797dd2cf7f21d75c06cc0650caafe956ecac5d807bbcce7771aba8934cac29fc35fad4af9d85598dde11c4e19c02da3386e5ae6c6a2678d67637d49a"}, {"line": 22004, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 66, "key": "fe1ce0623065ff195d21b0b5e241c72a539be7dc91d6321738987ecccf27ea4c0c383aa73658a8c33905a3f71a2f717c09d95990cc50baa82ac94ad4c26e73f4"}, {"line": 22008, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 67, "key": "6bd726d7253108dd12ecfc38607fbaf6c05eb7c51eb43baa19d01fb1328edc09d53ccf20bdcb5ea80cb882e0ba390ba2d486b05bc839a8c29cf2bfeee657f48d"}, {"line": 22012, "relation": "association", "evidence": "The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 23, "target": 35, "key": "89ffe75e4f116ef2af156953cc0e67798f957893fc4f5e3c2d65fa426a8670b612daa26a93d2bb498c0e0bdc7a79aff76781d8c3ad57f2190a09c0007056d99f"}, {"line": 18321, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 69, "target": 25, "key": "e20a6149450cf9e3ec8c6d821e340f58596920c070233fab4a6daf82a718a2db75ce92527d78e7a9d66bc2952a6a4840909cafdb1884e2945561863343948fe5"}, {"line": 18325, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 69, "target": 26, "key": "78f9d5cc50d866a076312f276830619bb39fbfdb551c8327d618c5f013816c722ee3a729e1fab2e9ffc52c44fcaf9e9dcfe5a78fc823447cb1abe77fac958002"}, {"line": 18329, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 69, "target": 27, "key": "6e77d31c49b5cad43e01f8e5c451c58f992c3b7b0c9edb95ded3e6199a17c82ea198840a8c452ae73ad74786874ddc26667e95a8d9f13d29e8e28f953d5f08e8"}, {"line": 18150, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 41, "target": 5, "key": "ad2f7d327c12543613d2e79039e4b999e6da9ee3609be0281e46fde2f40d877f9b4bfcc7f4286bea8a24ab17de278226371983c2906d31f12df60766c1cee8e2"}, {"line": 18194, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 41, "target": 6, "key": "d461ac095ccfcc406073a0e76283c6dbab093e233117ee60b7ba3882f68eba5dc413fd6a52a2cab6fde19bbc9991218cf0a96c7fe2da424c0a7ce7baab89d739"}, {"line": 18174, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 46, "target": 6, "key": "cf7be62d797efaba525afa6b7fca4e15478786059c12fdb4665146f8a9fbd9503793748b92a5317a4ca0415280f83ad74c70ed80363e6d0c7fc5f678e8e980a5"}, {"line": 17906, "relation": "increases", "evidence": "Furthermore, both pharmacological alpha-secretase pathway inhibition and sAPPalpha immunoneutralization approaches prevented etazolate neuroprotection against Abeta, indicating that etazolate exerts its neuroprotective effect via sAPPalpha induction.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Jul;106(1):392-404", "reference": "18397369"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "source": 13, "target": 29, "key": "051f0bafea6168b246d747894d22fee555b8933e332993af446f721ce628464325be717f60d4d920f57dd238ac101636fe90fa2a00bf1a1ec2a40e4222a01141"}, {"line": 22018, "relation": "association", "evidence": "Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7", "reference": "19909279"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 22, "target": 49, "key": "0ebba4aae9d28e147e1e0e06a0d1b045f2ae974f6e0352b2921c32b6abd8aac932d6f6aad48b1477f6dec9c03bd548e35853a717a07bbc7fb0986c79521600cc"}, {"line": 18142, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 39, "target": 5, "key": "ec77b565e66bd5e6c44ea30d38cdec6c58cafbd5b96e2cd220e23aa9e644171bcbfac717014e7d32d1875fc98cb468d5fffa8bf5338d82fa8d9f12c9b07c62b8"}, {"line": 18186, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 39, "target": 6, "key": "1e558e1ee13734987bf68a9f65761da56a5d67a5d36541a62b193559a3857276029a809cfff8d32ad05b13afd4c5a271f00183a321568d01debb519467ea46d5"}, {"line": 18146, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 40, "target": 5, "key": "2366657ad3b47788b51d95643a74f629af2238babb56e2d72e8de5b00e688298908513ba93309138e3d7ce849acc4e560d39461dabd4b07e01c2b3af73a03529"}, {"line": 18190, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 40, "target": 6, "key": "0efb64670a152dc78fda51c7546d758ab0f78bbe1d74901135f58d1f3add4592e118e19ab218ce1a7b61f7a91a7ece82d9098077ca84df14376681d1578c8703"}, {"line": 18154, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 42, "target": 5, "key": "b3532aa7ee80edc3ad15ccc17728eddec9c2df8cec1f6d970dbf5660fd2f3acf11fd0084ebcaf427e45f16dd04f929fe52ed58fd364af6ea4d2134f51d5f94b2"}, {"line": 18198, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 42, "target": 6, "key": "27572b029b54a1c24a3c647a1911056b2095717b7a4e36ed7569cbda07de7d253e4b4a936ed8419a40c477dcf68df114d26d6aa1a14dcc2af6233044d74ef1d0"}, {"line": 18158, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 43, "target": 5, "key": "1f2af5ec5bec979c567a89b0e52c0babd73a6348891ec3e724a3b4c1b8c2cf30c4030ecaa81abdc8c12249b5fa242813cf64f205173d9d4161661a65f3a13e5d"}, {"line": 18202, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 43, "target": 6, "key": "0f330368b23f2561d2dc4a106d47b7dfbb7c38a2257973af48956c556c7fa81c0255a3073780284b1cb16b308dbd0e5ea93a8953e5136d17811955a6f5bb39ff"}, {"line": 18162, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 44, "target": 5, "key": "99879e94cdb94cc5c1a5057b918b363bdc5b1f2fa3875f27baff44536c8e7f9f194bb64e84e9e29f8e41b03762c0ae1ede92f0d8b8ea52e7b30403cc2ef52a9b"}, {"line": 18205, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 44, "target": 6, "key": "0e04a448e8e9dad10715d70ef5d5f6173ebbebccb90f1940bc9f1b51cfa245072fb840e9d3a704d3d33a2737290d686de7f460f37a205a39e3c4f1a9fce3eb66"}, {"line": 18166, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 45, "target": 5, "key": "1e6adc6a53b7d6bbaf171a1fa4d9efac42bda7c4ff323d8f5d9083922a3c6aa1a005a2d01f264263269eb65d4f675d249baf1e468ad13c334c636303ef7c2d6b"}, {"line": 18209, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 45, "target": 6, "key": "7ff283b165d3da2758a2418613c281ada0460d9b151681d56abe0d06ea66b5a22f252e3fae55b6f65a597e0af0b612a473b8b46f70f0d9db0680f8f841de5a3c"}, {"line": 18170, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 38, "target": 5, "key": "b67a3760e862dc184ca314e336a03d1ba8414784e525bcf31fd6c4b30e685220863b2773d7edbf822667c0473b1a5d04caa1a6ffa8d3861f2ab5ce4b6bcd46fc"}, {"line": 18213, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 38, "target": 6, "key": "ceea92885ecf7ce2dad644a6d336a1baaf3a07a45fb3272a890cc156917ec677688a73ce887dbec66fae5a36084622e4222bd38d316edcc543ced546400c2a9c"}, {"line": 18178, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 47, "target": 6, "key": "bbd66d30ac570178a41d1db8003e19ac77551921a74e2f438e57293e6355957ab51d71ef3c8b60df20846d7bd2699a308310a39d2b347bc4755ae12325efc3a6"}, {"line": 18182, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 48, "target": 6, "key": "4dfa019ca801856bcf6c39abb72e86cb15f338a807b9cb444ee92bb102f4c08c994d125c52fccdf0e75066b367ec743bf2f7945c7eed305c2024af245a38251a"}, {"line": 18098, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 39, "key": "08270f903e09c8e389f9b6e4df24ff4f76ae1772f016465931e2c726a09afafe9e04c9a5f68c3e45a377578ef2269a1b856173a181d761e16acca1ccbee4c944"}, {"line": 18102, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 40, "key": "05e9abdde1fdc5a657fd1e4867cc17f44f558775fdc6d571e7a276352547ae2e9483aca24b2b00be46614bdc2b347175ef2bf4ee378ec5feeb1999722db66d2a"}, {"line": 18106, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 41, "key": "b83d99ea9e8f74dd2b4f4a2112e2964b237e84943287312616b80f1778c5e5858580c97eb9e8152b2062a2a992cd9671a6b681122657183cbd6be43941694595"}, {"line": 18110, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 42, "key": "9791c52f68d4ec0eca2484db336b07f982b06727a621b36da2a5d21c182fc52df492cf7c94323251a1ce886c3d1213153f694e105aa46e7f6361224d0bbf199d"}, {"line": 18114, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 43, "key": "385d44bba71fe4755f359775fc3d108941b2dd482fc550b479b3595334f2c7bdd42af936475bba0f3711c6afcd809b7fd57e8ea69e2162714f11b287c9bbf345"}, {"line": 18118, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 44, "key": "b1340589f4856d1ce9351543166fdcdca56651ac12fe6677d2801446a5e5bf1625cafb6653d2bf5b04430fa57b0c6debb3aa14ece1b01e4e4088c5dd5e1cf86b"}, {"line": 18122, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 45, "key": "f05a2dbec2bbf48f6d1747399ac29408810c31a21d0be02db7d4f6c90d28373d13a63a818a14f5b951c92d6c6eddadab842e01f88b636535aeb3718e0659cbe9"}, {"line": 18126, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 38, "key": "5d33238700595285d88b8eff2d544a0cddbc5459dc9ebcc3fe76841b23f62b50e35f033abbf8025ae14a25d338d1853c7822ce358611de65bb12970dae68f6f4"}, {"line": 18130, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 46, "key": "5b0fb4b8b57ba4bfb5be53d86dd0cbfa71d4113e75dff6e2f5fe3578a447ce381996ef18e1316a23022d3aead52f90b794b0c2708bb141576e4b483f58d1e72c"}, {"line": 18134, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 47, "key": "4f618742934b97fbd011564622aa1dbe0fdeb24f482bcf369fb7428c7db8104b826c7ce1d70eb2d136962cd804591995773aff1d921b05113a2adf0574f884c1"}, {"line": 18138, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 48, "key": "3f4c726b255da4c567887b0cdd2c0faab03ff99a7108f3a812fe1000535d0b8893045943b8616b162ff33cdf979a19af4f0be58a0093bd2f08f5003c437a038a"}, {"line": 17966, "relation": "isA", "evidence": "EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2011 Mar;8(2):203-12", "reference": "21222604"}, "annotations": {"FDASTATUS": {"Phase 2": true}, "Species": {"9606": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "source": 10, "target": 3, "key": "17a1c9d15d7237a79c3674b919b7d951802e9c906d64e60aa7833a37e2e220e1c0f9ad0e73575074abbaaef6d1a061260003acc32d508b52269497a9ac0594a4"}, {"line": 17898, "relation": "increases", "evidence": "Furthermore, both pharmacological alpha-secretase pathway inhibition and sAPPalpha immunoneutralization approaches prevented etazolate neuroprotection against Abeta, indicating that etazolate exerts its neuroprotective effect via sAPPalpha induction.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Jul;106(1):392-404", "reference": "18397369"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 10, "target": 13, "key": "36c4f8806b3540fd94d42bc22d5b3a5af44ceb5f54ee94c288696bc2e1f07ec0ea0fd2fb527cc857bd69fbbe114ed81a9a9017bbfcd23328595353707da51267"}, {"line": 17934, "relation": "increases", "evidence": "Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2010 May 25;634(1-3):95-100", "reference": "20223232"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "source": 10, "target": 13, "key": "1d9d6a519b56ae92a8292aff9ad53580a1e4b0e06dc7489a3e912b4b7d4f192b9380bf40561d782586ae90e0fe6e8cc517f38c0432d73315416295f4562470c5"}, {"line": 17977, "relation": "increases", "evidence": "EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2011 Mar;8(2):203-12", "reference": "21222604"}, "annotations": {"FDASTATUS": {"Phase 2": true}, "Species": {"9606": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "source": 10, "target": 13, "key": "5d2d6afb9ae5d44e7c4f680ab373374b344e9c97fcf6b21023f3f8694c476d565074139fa6de90d0f54e79c824df6ad1b488db9581b254e660edd5eec4838938"}, {"line": 17902, "relation": "increases", "evidence": "Furthermore, both pharmacological alpha-secretase pathway inhibition and sAPPalpha immunoneutralization approaches prevented etazolate neuroprotection against Abeta, indicating that etazolate exerts its neuroprotective effect via sAPPalpha induction.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Jul;106(1):392-404", "reference": "18397369"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 10, "target": 29, "key": "e40048fbaf8aa4a9dbf01d6dcde108663ac096320c08001fa431bc747cf31bd93a3da372e340d96b282f3856fbdc2901047bf964dba037c9edd4e153b4b51865"}, {"line": 17926, "relation": "isA", "evidence": "Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2010 May 25;634(1-3):95-100", "reference": "20223232"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "source": 10, "target": 2, "key": "0b826f2d9946209deffaaaecc1bc7e6f468a987784ebec580c3e98dc308991df401be2d73ab21d9bf08fe3538c72f335f4e9acb9669b0642f91180b437b4e634"}, {"line": 17969, "relation": "isA", "evidence": "EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2011 Mar;8(2):203-12", "reference": "21222604"}, "annotations": {"FDASTATUS": {"Phase 2": true}, "Species": {"9606": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "source": 10, "target": 2, "key": "249f289ae341c831701514e004e66be8d2fe1dfd45c425646b231fdc23893cdf6b6b8f58c2252b5e3255962e2bddd6fad393e82a5b2e7d6a2be38295c8c05a5a"}, {"line": 17929, "relation": "increases", "evidence": "Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2010 May 25;634(1-3):95-100", "reference": "20223232"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 10, "target": 36, "key": "1cd5232a254b7450c41d089f33b8e4c84f2370d410e1573dc9645ccec3b5b67f4b76ad73c247dc3a3b2ea673a27183f9c5c4489fc65e9c85749f0c3a3e5f0713"}, {"line": 17972, "relation": "increases", "evidence": "EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2011 Mar;8(2):203-12", "reference": "21222604"}, "annotations": {"FDASTATUS": {"Phase 2": true}, "Species": {"9606": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 10, "target": 36, "key": "f766293c6302ab8e7da6cf7412a7bf384fdc89140628eaa591da7718f869001aa173e36660d3cf3adae16489c337527bdbe9eaa8c7937bdb175ee8199fb1c856"}, {"line": 17945, "relation": "increases", "evidence": "The combined behavioral data demonstrate positive effects of etazolate on separate age-related cognitive deficits, using a complex task based on naturally occurring rodent behaviors.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2010 May 25;634(1-3):95-100", "reference": "20223232"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 10, "target": 19, "key": "9c23ee56b69b5f52e0533b0ba0cdfa004c566ec23c52196629f66f8e014cfa22229fdef358d1eeb44c8cdc8534caed3054b724f070da1ed854a9ffa7415b9b01"}, {"line": 17880, "relation": "isA", "evidence": "In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Jul;106(1):392-404", "reference": "18397369"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 15, "target": 3, "key": "15a11e74f554ec4ad38cc53ef1a8e2c3cce8ff4178dc532b090b9813c31ec36118623c49a494ef2900b52be0112454d6ec3fa16212ef8876ff194ec016ff3f1f"}, {"line": 17884, "relation": "increases", "evidence": "In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Jul;106(1):392-404", "reference": "18397369"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 15, "target": 13, "key": "c4e96d72f4e7eb4b2a9f4a6a10ea4f44e3695d808b069bbf2a9f41f9b28bb9a106c911ce35e6576f4d9e418a609dbcb3ac6d47229447d732302190bc55eae318"}, {"line": 17938, "relation": "increases", "evidence": "Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2010 May 25;634(1-3):95-100", "reference": "20223232"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 15, "target": 13, "key": "e98bfe79ccd0887a434395e05ce9c5e2b25f4f084c23dc3edc371c0cbbb674b51744377071e12ee4c93ceb98effc26f269a5c7d6bdac448d6c5421b7183b8282"}, {"line": 17888, "relation": "increases", "evidence": "In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Jul;106(1):392-404", "reference": "18397369"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 15, "target": 29, "key": "9df2e15c2043f234eb0deeccd2a84b6d08d2894866e9b291bab87f79ee1f650db41ff98dd769d483d343ddecb7be329abd55266acc19f4651de8266947424ec0"}, {"line": 17993, "relation": "increases", "evidence": "Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Psychopharmacology (Berl). 1997 May;131(2):130-9", "reference": "9201800"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 12, "target": 25, "key": "c5d75c33fa400c4fe3d320d209a118c1524d4bdc5b98bbec4afbd55a758e8bdeef1753ec8340f34372ccde45e6796b01240ec11ae4e617c1d0b0d39d1ba4a28e"}, {"line": 18007, "relation": "increases", "evidence": "The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.", "citation": {"type": "PubMed", "name": "Psychopharmacology (Berl). 1994 Mar;114(2):200-8", "reference": "7838908"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 12, "target": 25, "key": "d6da75edb697c35ed099e7074c158673278021a581240dd6ddf57b852a87c7891f1ccc042e4aa896d9ed17f20db2be5825aaca57605f95f4fd0002fa5eaa4b19"}, {"line": 18400, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 12, "target": 25, "key": "f3c1ad464041d2bb4641d16aa12d10cd1d5f432116f9e02b6582ec55c283dd599cb2fab3699f8dbd1af92aa2166e7bcfb8295245f8ad95abbb6008a7ed639216"}, {"line": 18024, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 69, "key": "5132abfdd5597641e6c052ea85ac22fac7d6f719e52a1e1f50cc2a4ea003760ff84b56c24585175f053dfbe11e776ac95869b83ed5a12dd50f85946f12fed185"}, {"line": 18313, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 69, "key": "21ca4ed6246f7cf9865f78bfb15b5431c491e68f518ef6a58586b42f9d220b2440f51241129067ca300319ff54cc847122ab7208470ec766ad27b937c27e5052"}, {"line": 18028, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 39, "key": "7ea090d2e86466135a92631f2206f4da9368e19ec70fadb6eccadbcc10a17a7e63b0ed6d938f1e150ce1f21abc283192edf8ca2fee6a5ff1cfe3d253405d9ab4"}, {"line": 18032, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 40, "key": "142442c05bcc95c4900eb4c4a5328f2eaca1d367d110513660ec0cca4ff8de5ff9b50dbc75ca8a49ac1bcf720da29006c9049e6461c274a4273260822b0379d8"}, {"line": 18036, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 41, "key": "4ef37a9824955c6bb1c22f7e7a93d382dbde9cfabbbcb423d8641449e6a82cdfe85d22467ed342415d2620cac6ff7d116742b67728d7a903847cf5559323e07c"}, {"line": 18040, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 42, "key": "0deb641164367e97795ad293d15d1698535e0ecd3210b62f45886d5f463e13d5ef616f66506c3b12dc2156eb19423e1b9d275fdbe0b5ca63bb17dcda3d0fb481"}, {"line": 18044, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 43, "key": "1440605f2d5a58efe7a1d9ff77de0f30a0a26715a3a32b398858d1d229f56cda60433f17601332dbe6e7c5e80a7d24c88c06efad86d8a2b68185d6990c88f9db"}, {"line": 18048, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 44, "key": "b3f3f5614d1a1667a7812cc225ba14c8720b9b419805d6f0efb9b4d55d280b84ea5d3fcc723d4ec78c13a4fdf1b050cf037518c2dec5123c50b7401d37792e1d"}, {"line": 18052, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 45, "key": "cc70739d14f8740ad06e34ac2199c335cdf421b01d2b4a9fb5f54ab4c5c2ffe46cbbb9b2939933c681169981dd3e1c8dd4d5a872edac008f09a253d641fd4aef"}, {"line": 18056, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 38, "key": "af720cc589fcd6f945e4517ebd1e6b9819a4312c1347d3d6c6d2ecda0e5c0e8e230606e33c2ce7724b1c17fa4230824805aaec793b556fb2c964fca1d89159c8"}, {"line": 18060, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 46, "key": "293f4e7ea15defbae3d442c4d92098b6db577a3af113a0465bbaece199c73a4a3f7f35ff2ceb534abb588a610801768740ac683ff0e338112f0b84cedfa0ce8c"}, {"line": 18064, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 47, "key": "9f77159c0976e49581e6f97abe9dd71cbc9734196cf4ada602f359f215ccae86a42207f08547654dce33912c39919dce36365a3b84d646269e962e1699b5eb13"}, {"line": 18074, "relation": "increases", "evidence": "In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 71, "key": "c6fbf41027af45222315da1a82430cae7535ddda0e5e6d5ef0733a0219ed0bc983468e09e09d0c4d46423ebee5cb0444cb10b02c4d064f54ff4c728a6e93f8b3"}, {"line": 18082, "relation": "causesNoChange", "evidence": "In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true}, "Confidence": {"High": true}}, "source": 12, "target": 21, "key": "7188909807aeb653189f5f578144c202d1160574d2a51e5d5b502bb0c84a844001008adc9c4a5687592034e629a2733546cc944aa8c8919793a83341ef1123e6"}, {"line": 18240, "relation": "isA", "evidence": "The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 12, "target": 1, "key": "1c6824d9e4fbe2100aea1cfc5f4d1a5f5b629c0f13b2bb735e7a14a4c0eb15f2e4fa5326f505ee11d942b94a26cae255ee00682964a47198d32ea133dda68303"}, {"line": 18297, "relation": "increases", "evidence": "Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. ", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 12, "target": 20, "key": "4dc96a936c87649c4449ddcd34dbb60dc1dd65582f03bbac9bc6fa650eb24f378c39dde4aad737851f9cdab570f9fdd3eb33b1e88bc74b517f5938cce051b408"}, {"line": 18301, "relation": "increases", "evidence": "Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. ", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 33, "key": "5efdb2f65f191997707e7d260a3f01b0127f04176748ee9d68750b5c9a572e67cfe2fde13d5b7f3801afec4a047cee8041457deefc8f60f7addd03e6222cdad9"}, {"line": 18317, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 12, "target": 33, "key": "04777800bea8e9ba574a16c5002232424a1bc493fadea7ce2418ae6dd868c1a08cac3dda9904f74727e2be156cfe304d688f327da2eb1a712e18a24e28e5f2ae"}, {"line": 18352, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 12, "target": 34, "key": "9536c7493472d31c1b74377372aea293cbe40240b4b69b1650f96ac394c07fcfca544b0ba80a81029b539bea6a0e6a4aac31363fa56ee63a7ba751e1edd66b9d"}, {"line": 18305, "relation": "increases", "evidence": "Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. ", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 33, "target": 68, "key": "1e13f10c7776363d5720bfea5a23b2461bdc0f453fe765394bb904d230b96b74b0965160bcfbb4ba0398b68c526754df56477a9f6b22167817ea4607aa017d2d"}, {"line": 18356, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 39, "key": "c15cbfbea578248782c7ee0d0d0ea07fca1b3db05f4e6cadf86f67f0b5a0d6177aa60b7182bc48e9e771358312114e6e09d314238bcfd1c1e1ee51d3e29baa81"}, {"line": 18360, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 40, "key": "7d78af86433871d2ed6aceef370363ad510d0eb3b3f58446b6f9a5d4541a9778a14bd3648c249bb23bf401459f7ee680ff3be2a013411418059931832847385d"}, {"line": 18364, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 41, "key": "14dcbf6022ca960fdacf0d0be56391cb691599442196d26fd96bbc91283ac2302a2439d156d1ceed7e7a65d8d5f21ef2af9ab139e6e7c2851c1ed687f64b09f4"}, {"line": 18368, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 42, "key": "aacf431c7e25d1071f5016adeb95789aebc02dea89e65b2d9b95799759ab7c9aef46f2a5d27e378145bcd42483e7753f44503c147c994252508a5e2446a4a064"}, {"line": 18372, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 43, "key": "9edf0fea99305ddbb5616c2921d19e5789cd61ca2e8d105837a64e71fac2c77058083f38cbd48c8ca834faa242f3a42dba0ec02eabf670d4c2c5a4ea1aae6787"}, {"line": 18376, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 44, "key": "635b09bd62bf65352db23db15161ead3026e96151a329cfd23933d4e8e57ddb9faa62ddafd449e93955d48dabbbd5b3c1d1af6c8916d7fa714cf2cdfc0098e02"}, {"line": 18380, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 45, "key": "065ae4e7de309a15ceaacdda36889af67508c565b585944a8d1f88c68deb94c8371fb9c86d76fce80aa273e40778847bc3b8c0bb2192bf121bbdefcd109c24eb"}, {"line": 18384, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 38, "key": "b69a202335dd28814178b8f6c4b4cfda2e2588e60c125b0e92375c15c1f5e585bf51cd062ce7b08ad0343e5734e5852a4ba7ad680bb56cf7a6d709e6d2e48753"}, {"line": 18388, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 46, "key": "277452498133afc65f5b0a570479aab3aefce23e4e26677e591be293669d22ec5d93a1b0f95de45c406775567c3dafdcfcf97948a2b684718710c5d28b45c14e"}, {"line": 18392, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 47, "key": "3e333f56c528243e5322fd75b70557fe62ab1dfdc45ad31c06d3c1739e513abda670ffdddaf586c18982e45ea46ff5fbf858b991110449a0e690076f711efb56"}, {"line": 18396, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 34, "target": 48, "key": "342d96634f1a6a2baa83458152c4d0b98860afe047f8576aa7919508cd28bd27ec77e2af37ce4ae4a9c9a8ed18c1a73392886d4db606f59a601023039e02860e"}, {"line": 22124, "relation": "increases", "evidence": "Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.", "citation": {"type": "PubMed", "reference": "21969301"}, "annotations": {"Species": {"10090": true}, "MeSHDisease": {"Glaucoma": true, "Alzheimer Disease": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"Medium": true}}, "source": 14, "target": 83, "key": "8b3e05b28ff96b7d4784abeef0d67842b544a7fe4699a237ed3db4deccd82f0c9c41956c66c9a41da8b7dd0abaa7ff3931d0f54749bc43d5a4f8c666d995a9a5"}, {"line": 22147, "relation": "increases", "evidence": "In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.", "citation": {"type": "PubMed", "reference": "21969301"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Hippocampus": true}, "Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 14, "target": 49, "key": "c33f714fdd96bc6cdcfe70d64a38bda209d1bb91e3e04bd6734e1871e261f6cf96cc42046eebf8013501233104c7d512c3c33bfe447f55cd8c89dc237ddb2a0a"}, {"line": 22191, "relation": "increases", "evidence": "Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.", "citation": {"type": "PubMed", "reference": "21969301"}, "annotations": {"MeSHDisease": {"Glaucoma": true, "Alzheimer Disease": true}, "Subgraph": {"GABA subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 14, "target": 28, "key": "02145f09d2b18b3b87c998af45dabdc199bafca8a221313eceec5fbe3e28d1a095e943afa2da80fda70afa82fa87a389a4733153e2ea5eb2f91ba97f97d780e3"}, {"line": 27587, "relation": "increases", "evidence": "In addition, TNF-alpha can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "reference": "24966471"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Glutamatergic subgraph": true}, "Confidence": {"Medium": true}}, "source": 16, "target": 18, "key": "7bc603bb8e55f6f16ecf70f17b62faa1da7606d3eace7e49fbbdb30b313bc03ebffada2b7fbf689574f8f565510566d2f3f85bd50c93088404e8c5855b6828fe"}, {"line": 41251, "relation": "increases", "evidence": "In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid beta peptide (Abeta) and the Abeta x-42/Ãâbeta x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.", "reference": "20888417"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 51, "target": 17, "key": "84d22500737c41ff7062d30cf821eead012e4ab50a64d9feef1a357b197026b4a8593eeea283059892b3747b60fd32f6652c38ebc7f66d835ad6e17f7470cc04"}, {"line": 41255, "relation": "increases", "evidence": "In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid beta peptide (Abeta) and the Abeta x-42/Ãâbeta x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.", "reference": "20888417"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 51, "target": 31, "key": "2b2077da95d8b699e597670ea04e409ebbccbc817bf0a238cdbfbf9134e8f08d5b31150d063059d6ab9eda316deaea9e05ba78d9f45c919003029a53ff1f94a4"}, {"line": 57602, "relation": "regulates", "evidence": "Estradiol affects the expression of GABRA4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16000229"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"Medium": true}}, "source": 9, "target": 87, "key": "5b35eab38f749a988f94c8c93adb4f543e617243f82d71eaf41ed0f259f6466b0991c4fbd0c7b53f09ee7edf2d057c084f65aaa55b7e8a87cee4705e12223306"}, {"line": 58455, "relation": "increases", "evidence": "Estradiol results in increased expression of GABRA3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16000229"}, "annotations": {"Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 9, "target": 86, "key": "3fee8560ceb23996869ae0a89634d64594f83f9b5a3e26f86c6a1335e3bad1d201ec1006f775041fee25a05a0e81bbd2e571afeded9e0ede403a428655ab2dac"}, {"line": 60313, "relation": "increases", "evidence": "Estradiol results in increased expression of GABRB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16000229"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 9, "target": 89, "key": "6bbd765279468b3b4e70193d2a5b5ccbcaa985f5abc8befde78fd0f1036c3ab2351ddefd8bb9c3ae8b02659ca3aa0681113de0d0dd0189b8d568c92f318fd22e"}, {"line": 56947, "relation": "increases", "evidence": "Copper Sulfate results in increased expression of GABRA5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 4, "target": 88, "key": "a0e50fc031f9cf74de05b020f0cf7ae9171db49ffaf82aee86c23676dda8c24461f161b8203fafa15c18a788002219812a0b1d249c66a8aa3970adf25bf0e152"}, {"line": 60296, "relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of GABRB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 4, "target": 89, "key": "65cb982ec549815a03b6863c86a44fdcbecd5ad2220fae3f7575d3cfd758e685a3fc00efb74b60bc5654718219a7e000762e76c649f11334aa5ba3f3b67f014e"}, {"line": 60329, "relation": "association", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GABRB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 8, "target": 90, "key": "6b9f0ad5c39ccda20cb10ee1bedf36ee7ee24d805dbded49ecceef11c2c93696317d08ee555d10a47a7ae766a6a280365628166cec6f62d66b1ea06f4a312caa"}, {"line": 60329, "relation": "association", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GABRB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 8, "key": "b85d1d2ece4ff7375ee367af66d980716734d5e516a56d6e22fe1f5b415925fd4656ba91c429ea386270df168ce467de956131ee8e72e310f99b1c6b4ff3da8d"}, {"line": 57725, "relation": "regulates", "evidence": "1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21729720"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"Medium": true}}, "source": 0, "target": 52, "key": "42541b27e8e0b44849565020855817e4f1fa7e7a56579e7f88d2fda907962100af5d3f899871eee25f65a2368c15c0019652a409afba1a6efceda64080a5fd46"}, {"line": 59896, "relation": "decreases", "evidence": "GABRA6 protein mutant form results in decreased susceptibility to Midazolam", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12031754"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 7, "target": 57, "key": "c7bd9bc21b8e83576e42b4d4b8c6849cc86a625d9d8514db067084485982d171eccd84c85619a83caab4ab89b0629220b20d4ed3d4f9be42d9b805b3c055c304"}, {"line": 60346, "relation": "increases", "evidence": "GABRB3 protein results in increased susceptibility to Midazolam", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9523823"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true}, "Confidence": {"High": true}}, "source": 7, "target": 84, "key": "9415347a93a2a4a41cbc1cbde6d1514b34cd14d9c608d26417dcdfa09d659c9961bd0a5a06cf4a6ed7484715e21a03f32ea84278c6cd5fb8a6b54e5d3efaaf5f"}]}